Key result
Low platelet reactivity (≤ 18 units) was associated with a significantly higher risk of 30-day VARC-2 bleeding events after TAVI compared to patients without LPR (HR 2.10; 95% CI 1.17-3.79; p=0.01).
Why the study?
Does low platelet reactivity predict 30-day bleeding events in TAVI patients on DAPT?
Cohort (n=146)
Does low platelet reactivity predict 30-day bleeding events in TAVI patients on DAPT?
Hazard Ratio: 2.1 (95% CI 1.17–3.79)
Absolute Event Rate: 45.6% vs 23.9%
p-value: p=0.01
In TAVI patients on DAPT, low platelet reactivity is an independent predictor of 30-day bleeding events, suggesting a potential role for platelet function testing in guiding antithrombotic therapy.
No takes yet. Share an insight, caveat, or question.
LPR may flag higher bleeding risk on DAPT post-TAVI; leaves open whether platelet function testing should guide therapy.
Groß et al. (2018) conducted a cohort in Transcatheter aortic valve implantation (TAVI) (n=146). Low platelet reactivity (LPR, ≤ 18 units) vs. Patients without low platelet reactivity was evaluated on VARC-2 bleeding events at 30 days (HR 2.10, 95% CI 1.17-3.79, p=0.01). Low platelet reactivity (≤ 18 units) was associated with a significantly higher risk of 30-day VARC-2 bleeding events after TAVI compared to patients without LPR (HR 2.10; 95% CI 1.17-3.79; p=0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: